НОВАЯ СТАТЬЯ
Oral decitabine in acute myeloid leukemia: assessing efficacy, safety, and future implications for older patients.
Compared to IV-DEC, C-DEC provides similar therapeutic exposure and efficacy with an optional safety profile, enhanced treatment adherence, reduced treatment burden, and required healthcare facilities compared to those associated with IV-DEC, providing a precious tool to manage older and unfit AML patients.